Opdivo (Nivolumab) vs Jaypirca (pirtobrutinib)

Opdivo (nivolumab) is an immune checkpoint inhibitor specifically targeting the PD-1 receptor on T cells, which is used to treat various types of cancers, including melanoma, lung cancer, and kidney cancer, by enhancing the body's immune response against cancer cells. Jaypirca (pirtobrutinib), on the other hand, is a highly selective, non-covalent Bruton's tyrosine kinase (BTK) inhibitor designed to overcome the limitations of previous BTK inhibitors and is used in the treatment of mantle cell lymphoma and other B-cell malignancies. When deciding between these two medications, it is crucial to consider the specific type of cancer being treated, as their mechanisms of action and indications differ significantly; a healthcare provider can offer guidance based on the individual's diagnosis, treatment history, and overall health profile.

Difference between Opdivo and Jaypirca

Metric	Opdivo (Nivolumab)	Jaypirca (pirtobrutinib)
Generic name	Nivolumab	Pirtobrutinib
Indications	Various types of cancers including melanoma, lung cancer, kidney cancer, bladder cancer, head and neck cancer, and more.	Treatment of relapsed or refractory mantle cell lymphoma (MCL) and other B-cell malignancies.
Mechanism of action	Programmed death receptor-1 (PD-1) blocking antibody that enhances the immune response against cancer cells.	Bruton's tyrosine kinase (BTK) inhibitor that blocks B-cell receptor signaling in malignant B cells.
Brand names	Opdivo	Jaypirca
Administrative route	Intravenous infusion	Oral
Side effects	Fatigue, rash, musculoskeletal pain, pruritus, diarrhea, nausea, and others.	Thrombocytopenia, neutropenia, anemia, fatigue, musculoskeletal pain, and others.
Contraindications	Hypersensitivity to nivolumab or any of its excipients.	Hypersensitivity to pirtobrutinib or any of its excipients.
Drug class	Immune checkpoint inhibitor	BTK inhibitor
Manufacturer	Bristol Myers Squibb	Eli Lilly and Company

Efficacy

Efficacy of Opdivo (Nivolumab) in Lymphoma

Opdivo (Nivolumab) is a programmed death receptor-1 (PD-1) blocking antibody used in cancer immunotherapy. It has shown efficacy in treating several types of cancer, including lymphoma. Specifically, Nivolumab has been evaluated for its effectiveness in treating classical Hodgkin Lymphoma (cHL) after failure of autologous stem cell transplant (ASCT) or after at least two prior therapies in patients who are not ASCT candidates. Clinical trials have demonstrated that Nivolumab can induce a durable response in relapsed or refractory cHL, with a significant proportion of patients achieving partial or complete responses. However, it is important to note that responses may vary, and not all patients with lymphoma will benefit from Nivolumab treatment.

Efficacy of Jaypirca (Pirtobrutinib) in Lymphoma

Jaypirca (Pirtobrutinib) is a novel, highly selective, non-covalent Bruton's tyrosine kinase (BTK) inhibitor. It is designed to overcome resistance to other BTK inhibitors and has been studied for its efficacy in treating B-cell malignancies, including various forms of lymphoma. In clinical trials, Pirtobrutinib has shown promising activity in patients with relapsed or refractory B-cell malignancies, including those with lymphomas that are resistant to covalent BTK inhibitors. The efficacy of Pirtobrutinib in lymphoma patients suggests potential as a treatment option, particularly for those who have exhausted other therapies.

It is essential to understand that the efficacy of both Opdivo and Jaypirca can be influenced by several factors, including the specific subtype of lymphoma, prior treatments, and individual patient characteristics. Clinical trials and ongoing research continue to define the role of these medications in the treatment landscape of lymphoma. Healthcare providers consider the evidence from these studies when making treatment decisions for their patients with lymphoma.

Patients with lymphoma considering treatment with Opdivo or Jaypirca should discuss the potential benefits and risks with their healthcare provider. The decision to use these medications is based on a careful consideration of the individual patient's condition, treatment history, and the efficacy and safety profile of the drugs. It is also important for patients to be monitored regularly while on these treatments to assess their response and manage any potential side effects that may occur.

Regulatory Agency Approvals

Opdivo

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA
Health Canada
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Therapeutic Goods Administration (TGA), Australia
Medsafe (NZ)

Jaypirca

Food and Drug Administration (FDA), USA

Access Opdivo or Jaypirca today

If Opdivo or Jaypirca are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.

Buy Opdivo

Buy Jaypirca

How it works

Make an enquiry

Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.

Breeze through the paperwork

We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.

Get a personalized quote

We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.

Receive your medicine

Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.

Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.

Let's talk

If you have any questions, call us or send us a message through WhatsApp or email: